Skip to content

Cefadroxil

ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: cefadrox, cefadroxil hemihydrate, cephadroxil

OfpFDA approvedATC J01DB05

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cefadroxil is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1978. DrugCentral lists 2 molecular targets, including SLC15A1 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB. Recorded indications include Escherichia coli urinary tract infection, Infection due to Staphylococcus aureus, Infection of skin AND/OR subcutaneous tissue and Klebsiella cystitis.

  • Approval status: ofp (first approved 1978 by the FDA).
  • Molecular targets: SLC15A1 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (2 listed in DrugCentral).
  • Indications: Escherichia coli urinary tract infection, Infection due to Staphylococcus aureus, Infection of skin AND/OR subcutaneous tissue, Klebsiella cystitis and Proteus urinary tract infection and others.
  • ATC code: J01DB05 (First-generation cephalosporins).
  • Molecular formula: C16H17N3O5S; molecular weight 363.39 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (9)

  • Escherichia coli urinary tract infection
  • Infection due to Staphylococcus aureus
  • Infection of skin AND/OR subcutaneous tissue
  • Klebsiella cystitis
  • Proteus urinary tract infection
  • Streptococcal tonsillitis
  • Streptococcus pyogenes infection
  • Tonsillitis
  • Urinary tract infectious disease

Off-label uses (1)

  • Prevention of Bacterial Endocarditis

Contraindications (2)

  • Impaired renal function disorder
  • Pseudomembranous enterocolitis

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Solute carrier family 15 member 1SLC15A1unknownKi 2.14
Bacterial penicillin-binding proteinmrcA|mrcB|dacC|mrdA|ftsI|dacA|dacBinhibitor—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1978-02-17FDA——

ATC classification

ATC codeTherapeutic hierarchy
J01DB05ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › First-generation cephalosporins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Nasal oedema1054.1
Respiratory tract infection524.6
Cross sensitivity reaction466.8
Oedema444.5
Asthma426.4
Drug hypersensitivity402.3
Chest pain292.9
Wheezing273.3
Type IV hypersensitivity reaction225.2
Cough223.7
Pain199.1
Malaise185.9

Chemical structure

Molecular formulaC16H17N3O5S
Molecular weight363.39 g/mol
CAS number—
InChIKeyBOEGTKLJZSQCCD-UEKVPHQBSA-N
PubChem CID47965
CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=C(O)C=C1)C2=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefadroxil used for?

DrugCentral lists the following indications for Cefadroxil: Escherichia coli urinary tract infection, Infection due to Staphylococcus aureus, Infection of skin AND/OR subcutaneous tissue, Klebsiella cystitis, Proteus urinary tract infection, Streptococcal tonsillitis, Streptococcus pyogenes infection and Tonsillitis and others.

How does Cefadroxil work?

Its molecular targets in DrugCentral include SLC15A1 and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Cefadroxil first approved?

Cefadroxil was first approved by the FDA in 1978.

What is the chemical formula of Cefadroxil?

Cefadroxil has the molecular formula C16H17N3O5S and a molecular weight of 363.39 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1978-02-17
AgencyFDA
Targets2
Indications9
FormulaC16H17N3O5S
DrugCentral ID526
Interactive profile